Amgen's earnings call showcases a strong revenue and EPS growth of 3%, indicating a positive quarter despite the challenges faced by certain products like EPOGEN. The highlight was the acceleration of their share repurchase program, signalizing significant confidence in their long-term value. Yet, the unchanged divident policy amidst these buybacks, along with concerns regarding EPOGEN's future and SG&A increases, might lead to a more measured short-term market response. [1]
        